MiNK Therapeutics, Inc. (NasdaqCM: INKT)
Health Care · Biotechnology · US
$9.41
-12.22% today · -36.3% 1Y
MiNK Therapeutics, Inc. (NasdaqCM: INKT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $48.02M and employs 15 people.
Over the last twelve months the share price has lost 36.3%, trading between 8.48 and 16.93.
Tweenvest scores MiNK Therapeutics, Inc. across four factors: quality 33/100, value 59/100. Its strongest factor is value.
INKT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $48.02M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.40
- Dividend yield
- —
- Beta (5Y)
- 0.47
- 52-week high
- $16.93
- 52-week low
- $8.48
- Avg volume (3M)
- —
- Shares outstanding
- 5.10M
- Employees
- 15
- Next earnings
- —
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
- ISIN
- US6036932019
- Founded
- 2017
- Listed since
- Oct 15, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Amicogen, Inc.KOSDAQ: A092040 | $48.83M | ₩924.00 | -6.29% |
| Optipharm.CO.,LTDKOSDAQ: A153710 | $48.80M | ₩4,435.00 | -1.22% |
| GENINUS Inc.KOSDAQ: A389030 | $48.75M | ₩1,650.00 | -15.38% |
| Connect Biopharma Holdings LimitedNasdaqGM: CNTB | $48.27M | $0.77 | +0.58% |
| HLB Panagene Co., Ltd.KOSDAQ: A046210 | $47.81M | ₩1,400.00 | -21.08% |
| Sangamo Therapeutics, Inc.OTCPK: SGMO.Q | $47.64M | $0.12 | +9.52% |
| Werewolf Therapeutics, Inc.NasdaqCM: HOWL | $47.63M | $0.98 | +0.04% |
| Kalaris Therapeutics, Inc.NasdaqGM: KLRS | $47.61M | $2.00 | -15.25% |
Figures last refreshed Oct 18, 2026.